Premium
THE ASSESSMENT OF POTENTIAL DRUG INTERACTIONS WITH A NEW TRICYCLIC ANTIDEPRESSANT DRUG
Author(s) -
BRIANT R.H.,
GEORGE C.F.
Publication year - 1974
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1974.tb00219.x
Subject(s) - tricyclic , antidepressant , tricyclic antidepressant , drug , pharmacology , tyramine , phenelzine , medicine , chemistry , enzyme , monoamine oxidase , biochemistry , hippocampus
1 Methods for the investigation of possible interactions with tricyclic antidepressant drugs are described. These methods have been applied to a new compound, Ciba 34276‐Ba, which has been shown to have antidepressant activity. 2 In five normal volunteers tested before and during treatment with Ciba 34276‐Ba, no abnormalities of resting or post‐exercise electrocardiographs occurred. A three‐fold reduction in tyramine‐responsiveness was seen in three normal subjects studied, but no potentiation of the noradrenaline pressor effect occurred. One of six patients given Ciba 34276‐Ba whilst on long‐term treatment with bethanidine showed loss of blood pressure control. 3 The metabolic clearance of antipyrine was unaltered in two subjects studied, showing no evidence of induction or inhibition of hepatic microsomal oxidizing enzymes by Ciba 34276‐Ba.